ArticleRespiratory research2025
TET1-Mediated DNA hydroxymethylation of KLF6 promotes LPS-induced pulmonary fibrosis by activating the S1PR3/RhoA/ROCK signaling pathway.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Endothelial Cell Perspective in Pulmonary Fibrosis: From Cell Fate Decisions, Intercellular Communication, and EndoMT to Emerging Therapies.Canadian respiratory journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTen-Eleven Translocation methylcytosine dioxygenase 1 (TET1) plays crucial roles in organ injury and fibrosis, but its role and regulatory mechanism in pulmonary fibrosis remain to be elucidated.
methodsGene and protein expression levels were assessed using RT-qPCR, Western blot and immunohistochemistry. CCK-8 and TUNEL were used to detect cell viability and apoptosis, respectively. The DNA methylation of Kruppel-like factor 6 (KLF6) was detected by MSP. 5-hydroxymethylcytosine (5hmC) level of KLF6 was detected by the corresponding kit. ChIP assay or dual luciferase reporter gene assay was applied to detect the binding relationship between TET1 and KLF6 promoter/KLF6 and Sphingosine-1-phosphate receptor 3 (S1PR3) promoter. Histological examination, including H&E and Masson trichrome staining, was conducted to analyze lung injury and fibrosis.
resultsTET1 knockdown attenuated lipopolysaccharide (LPS)-induced endothelial-mesenchymal transition (EndMT) and apoptosis in HPMECs by restoring viability, reducing apoptosis, and reversing changes in endothelial and mesenchymal markers. TET1 knockdown reduced KLF6 expression via promoting DNA methylation. KLF6 overexpression reversed the effect of TET1 knockdown on EndMT and apoptosis in LPS-induced HPMECs. KLF6 knockdown inactivated RhoA/ROCK signaling and reduced EndMT of LPS-induced HPMECs cells by inhibiting S1PR3 transcription. TET1 knockdown alleviated LPS-induced pulmonary fibrosis via suppressing KLF6 and inactivating S1PR3/RhoA/ROCK.
conclusionTET1 promoted LPS-induced pulmonary fibrosis by regulating KLF6 and activating the S1PR3/RhoA/ROCK signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.